Genprex, INC 10-Q quarterly reports

Genprex, Inc. reports on its Q2 2026 progress, highlighting advancements in its oncology and diabetes gene therapy programs, while addressing ongoing liquidity concerns and Nasdaq compliance.

Genprex reports on progress in its oncology and diabetes gene therapy programs, with increased cash reserves from equity financings and ongoing clinical trial enrollment.

Genprex, a clinical-stage gene therapy company, reported a reduced net loss in Q3 2025 but faces significant liquidity challenges, Nasdaq listing compliance issues, and continues to raise capital through equity offerings.

Genprex, Inc. reports reduced net losses but faces significant financial challenges including a going concern warning, Nasdaq delisting threat, and limited cash runway through August 2025.

Genprex, Inc. reports its Q1 2025 financial results, highlighting ongoing clinical trials for REQORSA and efforts to secure additional funding amidst going concern uncertainties.

Genprex, Inc. reports a net loss of $4.3 million for the third quarter of 2024, while focusing on its key clinical trials and strategic alternatives.

Genprex, Inc. reported its financial results for the second quarter of 2024, highlighting advancements in its clinical trials and a reduction in operating expenses.

Genprex, Inc. reported a net loss of $5.97 million for the first quarter of 2024, while advancing its clinical programs for cancer and diabetes.